Axsome Therapeutics, Inc (AXSM) Valuation
Historical valuation analysis based on 500 data points (2024-09-23 to 2026-09-21)
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which ther...
Axsome Therapeutics, Inc (AXSM) currently trades at a P/S ratio of 14.85 (range: 9.94–95.80, 55th percentile — near its historical average).
Axsome Therapeutics, Inc appears slightly overvalued relative to its historical range, with most valuation metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/S Ratio | 14.85 | 9.94 | 14.39 | 95.80 | 55th | near its historical average |
Axsome Therapeutics, Inc (AXSM) Valuation & P/E History
Axsome Therapeutics, Inc (AXSM) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry currently trading at $205.49 with a market capitalization of $10.8 billion. This page provides historical valuation analysis for AXSM based on 500 data points covering 2024-09-23 to 2026-09-21.. The P/S ratio of 14.85 compares to a median of 14.39.
AXSM Valuation Metrics & Historical Range
The valuation table above shows Axsome Therapeutics, Inc's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether AXSM is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests AXSM is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Axsome Therapeutics, Inc.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is AXSM Overvalued or Undervalued?
Axsome Therapeutics, Inc appears slightly overvalued relative to its historical range, with most valuation metrics above their median levels. The overall valuation percentile of 55 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive AXSM is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full AXSM analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.AXSM trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.